| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8223683 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 5 Pages |
Abstract
Rectal cancer patients undergoing neoadjuvant CRT may experience a reduction in global QOL along with significant gastrointestinal and genitourinary symptoms during treatment. Moreover, provider-rated toxicity scales may not fully capture this decrease in patient-reported QOL. Although most symptoms are transient, impairment in sexual function may persist after the completion of therapy and merits further investigation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Joseph M. MD, MSc, Amol K. MD, Kent A. MPH, MS, Mark M. MD, Jennifer B. PhD, Susan L. MD, Nolifer S. MD, June MD, Leah NP, Jonathan E. MD, Theodore S. MD, PhD, Edgar MD,